BDNF and major depressive disorder: Overall, alterations in the levels of α2-AR and BDNF are closely associated with mood dysregulation, including PPD, with dexmedetomidine showing promise in the regulation of pathophysiological changes in depression as well as possible treatment efficacy in PPD.